Lipella Pharmaceuticals Inc.
Liposomal drug delivery formulations for therapeutic candidates in clinical development
- Sector
- Medtech
- Headquarters
- Pittsburgh, PA
- Founded
- 2005
- Latest Form D
- $9K, Apr 2025
- Total capital
- $11.4M
- Federal grants
- $6.3M
- 12 awards · 2015–2023
- Rank in peer group#43 of 79
- Private capital raised
- $5.1M
- 6 Form D · last Apr 2025
- 19 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 19 pending · first 2020
- Rank in peer group#7 of 79
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$9K
- Private capital raisedForm D · SEC · 5th filing$2.6M
- Private capital raisedForm D · SEC · 4th filing$120K
- Private capital raisedForm D · SEC · 3rd filing$2M
- Offering registeredForm D · SEC · 2nd filing$122K
- Federal grantHealth and Human S · Phase II · Phenotyping Interstitial Cystitis/Bladder Pain Syndrome by ICE-MRI Based Bladder Permeability Assay$680K
- Federal grantHealth and Human S · Phase II · Phenotyping Interstitial Cystitis/Bladder Pain Syndrome by ICE-MRI Based Bladder Permeability Assay$1.4M
- Private capital raisedForm D · SEC · 1st filing$405K
Show 10 earlier federal awards
- Federal grantHealth and Human S · Phase II · Phenotyping Interstitial Cystitis/Bladder Pain Syndrome by ICE-MRI Based Bladder Permeability Assay$673K
- Federal grantHealth and Human S · Phase II · Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation$585K
- Federal grantHealth and Human S · Phase II · Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation$656K
- Federal grantHealth and Human S · Phase I · Rapid Point-of-Care Diagnostic Kit for Mosquito Borne Diseases in Urine$211K
- Federal grantHealth and Human S · Phase I · Rapid Point of Care Diagnostic Kit for Mosquito Borne Diseases in Urine$211K
- Federal grantHealth and Human S · Phase II · Preclinical Development of Tacrolimus for Radiation Cystitis$630K
- Federal grantHealth and Human S · Phase I · Measuring Bladder Permeability with MRI using a Novel Contrast Agent Formulation$225K
- Federal grantHealth and Human S · Phase II · Developing Intravesical Liposomes for Interstitial Cystitis$373K
- Federal grantHealth and Human S · Phase II · Developing Intravesical Liposomes for Interstitial Cystitis Suppliment request for NIH Exhibiting companies at BIO International$5K
- Federal grantHealth and Human S · Phase II · Preclinical Development of Tacrolimus for Radiation Cystitis$648K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
66months
from Lipella Pharmaceuticals Inc.’s first federal award to its first private round.
- First federal award · May 2015
- Health and Human S · $648K
- First Form D · Nov 2020
- $405K · 1st Form D
- Awards before first raise
- 9 awards
An association in public records, not a cause or a prediction.
Standing among 79 peers
Line = medianMedtech · Instrument
- Federal grantsBelow median
- Granted patents#7 · top 9%
- Linked publications#1 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jonathan KaufmanResearcherExecutive Officer, DirectorLinked by 1 patent · $1.6M in grants as PI
- BERNARD TOKARCZYKExecutive OfficerNamed in SEC Form D filings
- Byong KimDirectorNamed in SEC Form D filings
- Daniel CohenDirectorNamed in SEC Form D filings
- DAVID BATTLEMANDirectorNamed in SEC Form D filings
- Douglas JohnstonExecutive OfficerNamed in SEC Form D filings
Show all 13 people
- LEAF HUANGDirector, PromoterNamed in SEC Form D filings
- Lori BirderDirectorNamed in SEC Form D filings
- Michael ChancellorExecutive Officer, DirectorNamed in SEC Form D filings
- Naoki YoshimuraDirectorNamed in SEC Form D filings
- PRADEEP TYAGIPromoterNamed in SEC Form D filings
- Ryan PruchnicDirectorNamed in SEC Form D filings
- THOMAS PETZINGER, JR.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 23- PendingSystems And Methods Of Detecting Interstitial CystitisUSPTOApplication 19200239
- PendingDelivery Of Agents Using Metastable LiposomesUSPTOApplication 18924830
- GrantedSystems And Methods Of Detecting Interstitial CystitisUSPTOUS 12,326,492
Show all 23 patent records
- Systems And Methods Of Detecting Interstitial CystitisAug 28, 2025 · Application 19200239Pending
- Delivery Of Agents Using Metastable LiposomesJul 17, 2025 · Application 18924830Pending
- Systems And Methods Of Detecting Interstitial CystitisJun 10, 2025 · US 12,326,492Granted
- Delivery Of Agents Using Metastable LiposomesNov 12, 2024 · US 12,138,345Granted
- Intravesical Delivery Of Hydrophilic Therapeutic Agents Using LiposomesApr 11, 2024 · Application 18011635Pending
- Delivery Of Agents Using Metastable LiposomesJun 14, 2022 · US 11,357,725Granted
- Delivery Of Agents Using Metastable LiposomesMay 5, 2020 · US 10,639,278Granted
- Systems And Methods Of Detecting Interstitial CystitisMay 19, 2016 · Application 14678638Pending
- Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)Feb 18, 2016 · Application 14862923Pending
- Methods and Compositions for Treating Gastric DisordersFeb 5, 2015 · Application 14376590Pending
- Compositions And Methods For Treating Underactive BladderJan 29, 2015 · Application 14225154Pending
- Delivery Of Agents Using Metastable LiposomesApplication PCTUS2014061769Pending
- Systems And Methods Of Detecting Interstitial CystitisApplication 62062339Pending
- Systems And Methods Of Detecting Interstitial CystitisApplication 61974964Pending
- Delivery of Agents Using Metastable LipisomesApplication 61894334Pending
- Compositions and Methods for Treating Under Active BladderApplication 61805114Pending
- Methods And Compositions For Treating Gastric DisordersApplication PCTUS2013024596Pending
- Instillation Of Liposomal Formulation Of Sirna And Antisense OligonucleotidesApplication PCTUS2010056224Pending
- Methods And Compositions For Diagnosing Urological DisordersApplication PCTUS2009069784Pending
- Intravesical Delivery Of Hydrophilic Therapeutic Agents Using LiposomesApplication 63280426Pending
- Method Of Treatment For Bladder DysfunctionApplication PCTUS2009039489Pending
- Systems And Methods Of Detecting Interstitial CystitisApplication PCTUS2015024309Pending
- Intravesical Delivery Of Hydrophilic Therapeutic Agents Using LiposomesApplication PCTUS2022079695Pending
Recent research by its founders
- Supplementary Table 1 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study20261 cites
- Data from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study20260 cites
- Supplementary Figure 10 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study20260 cites
Related companies, and why
- Origin Endoscopy Inc.Similar federal contract value in Medtech · null in contracts
- PROLOCOR INC.Similar federal contract value in Medtech · null in contracts
- MED-COMPLIANCE IQ, INC.Similar federal contract value in Medtech · null in contracts
- THERABRACELET, INC.Similar federal contract value in Medtech · null in contracts
- Progenesis Technologies, LLCSimilar federal contract value in Medtech · null in contracts
- OPTICYTE INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .